Fyodor Biotechnologies awarded a national science foundation SBIR grant

Fyodor Biotechnologies, a Baltimore-based diagnostic and biopharmaceutical company, announced today that the National Science Foundation has awarded the company a Small Business Innovation Research (SBIR) Phase I grant. With the $150,000 funding, Fyodor plans to further progress the development of its innovative Urine Malaria Test (UMT) technology.

“We are pleased to receive this award from the National Science Foundation from among what we can be sure was a highly
competitive list of leading-edge project proposals,” said Eddy Agbo, DVM, PhD, Chairman & CEO of Fyodor Biotechnologies. “We will use the funds to broaden the utilization of Fyodor’s malaria diagnostic which uses urine instead of blood, and thus can be performed without the need for trained persons or other materials, resources often in short supply in areas of the world where diagnosis within 24 hours is critical.”

Fyodor intends to demonstrate proof of principle of its next generation UMT for the simultaneous diagnosis of Plasmodium
falciparum
and P. vivax in one test. P. falciparum accounts for about 95 percent of clinical malaria in Africa, but only about 60 percent of clinical cases in Asia, South America, Western Pacific and the Mediterranean, where it often occurs as mixed infections with P. vivax, which accounts for 40 percent of cases. Such differential diagnosis is critical for both determining appropriate treatment and conducting epidemiological studies.

Fyodor’s flagship UMT product, which is currently undergoing validation testing, is used for the diagnosis of malaria caused by P.falciparum in persons with fever. Unlike currently available malaria diagnostics, it uses urine rather than blood, enabling point-ofcare diagnosis even in remote areas where laboratory diagnosis is limited or non-existent. The UMT has the potential to facilitate current global efforts towards home-based diagnosis of malaria within 24 hours in all cases of fever.

Source: Fyodor Biotechnologies, Inc.

Comments are closed.